Merck
  • Home
  • Search Results
  • Global changes in chromatin accessibility and transcription following ATRX inactivation in human cancer cells.

Global changes in chromatin accessibility and transcription following ATRX inactivation in human cancer cells.

FEBS letters (2019-07-23)
Junbo Liang, Hongchao Liu, Guangyu Li, Jun Qian, Ran Gao, Yanchi Zhou, Xiaoyue Wang
ABSTRACT

α-Tthalassemia mental retardation X-linked (ATRX) is a chromatin remodeler frequently mutated in many cancers. Despite the binding pattern of ATRX in heterochromatin, ATRX-mediated epigenomic changes in cancer cells have not been profiled, especially for the heterochromatin regions. Here, we profiled genome-wide maps of chromatin accessibility in ATRX-intact and ATRX-null human cancer cells. We found extensive changes in chromatin accessibility in both repetitive DNA regions and non-repetitive regulatory regions following ATRX loss. These changes are highly correlated with changes in transcription, which lead to alterations in cancer-related signalling pathways, such as upregulation of the TGF-β pathway and downregulation of the cadherin family of proteins. These findings indicate that ATRX deficiency induces epigenomic changes and promotes tumorigenesis through both genome instability and shifts in transcription.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-ATRX antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution